{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:16:57Z","timestamp":1790223417028,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,2,20]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Lenalidomide is effective in refractory advanced cutaneous T-cell lymphoma, with an overall response rate of 28%. Patients demonstrate a transient flare reaction in skin, blood, and\/or lymph nodes that may be associated with improvement in disease burden.<\/jats:p>","DOI":"10.1182\/blood-2013-09-525915","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T02:15:04Z","timestamp":1386814504000},"page":"1159-1166","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":88,"title":["Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1182","volume":"123","author":[{"given":"Christiane","family":"Querfeld","sequence":"first","affiliation":[{"name":"Department of Medicine\/Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Dusza","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019111818151516400_B1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas.","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019111818151516400_B2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"issue":"21","key":"2019111818151516400_B3","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"2019111818151516400_B4","author":"Agar"},{"issue":"26","key":"2019111818151516400_B5","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"2019111818151516400_B6","author":"Prince"},{"key":"2019111818151516400_B7","author":"Duvic"},{"issue":"1","key":"2019111818151516400_B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"2019111818151516400_B9","author":"Piekarz"},{"key":"2019111818151516400_B10","author":"Whittaker"},{"issue":"11","key":"2019111818151516400_B11","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111818151516400_B12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -na\u00efve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"2019111818151516400_B13","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome.","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"2019111818151516400_B14","author":"Chong"},{"issue":"4","key":"2019111818151516400_B15","first-page":"187","article-title":"Prognostic markers in mycosis fungoides.","volume":"30","author":"Goteri","year":"2008","journal-title":"Anal Quant Cytol Histol"},{"issue":"10","key":"2019111818151516400_B16","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/sj.jid.5700371","article-title":"Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma.","volume":"126","author":"Tiemessen","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"12","key":"2019111818151516400_B17","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/sj.leu.2404913","article-title":"FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.","volume":"21","author":"Gjerdrum","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"2019111818151516400_B18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents.","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2019111818151516400_B19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes.","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111818151516400_B20","doi-asserted-by":"crossref","first-page":"e64354","DOI":"10.1371\/journal.pone.0064354","article-title":"Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS ONE"},{"key":"2019111818151516400_B21","author":"Kotla"},{"key":"2019111818151516400_B22","author":"Chanan-Khan"},{"issue":"6","key":"2019111818151516400_B23","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00280-012-1874-2","article-title":"Lenalidomide in solid tumors.","volume":"69","author":"Segler","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"2019111818151516400_B24","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"2019111818151516400_B25","author":"Thieblemont"},{"key":"2019111818151516400_B26","author":"Witzig"},{"key":"2019111818151516400_B27","author":"Wiernik"},{"issue":"3","key":"2019111818151516400_B28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111818151516400_B29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12449","article-title":"Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.","volume":"162","author":"Vose","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111818151516400_B30","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"issue":"1","key":"2019111818151516400_B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials.","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"14","key":"2019111818151516400_B32","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q.","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"19","key":"2019111818151516400_B33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111818151516400_B34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1034\/j.1600-0560.2001.028004174.x","article-title":"Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting.","volume":"28","author":"Guitart","year":"2001","journal-title":"J Cutan Pathol"},{"issue":"18","key":"2019111818151516400_B35","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"key":"2019111818151516400_B36","author":"Olsen"},{"issue":"10","key":"2019111818151516400_B37","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/cncr.25748","article-title":"Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.","volume":"117","author":"Chanan-Khan","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"2019111818151516400_B38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2141.2011.08882.x","article-title":"Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.","volume":"155","author":"Chanan-Khan","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/8\/1159\/1378964\/1159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/8\/1159\/1378964\/1159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T18:17:08Z","timestamp":1574101028000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/8\/1159\/32833\/Results-of-an-openlabel-multicenter-phase-2-trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,2,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2013-09-525915","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}